Zura Bio Limited (ZURA) – What Are Researchers Saying About This Stock?

Zura Bio Limited (NASDAQ:ZURA) has been given a consensus rating of “Moderate Buy” by the seven brokerages that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $17.00.

Several research firms recently weighed in on ZURA. Wall Street Zen upgraded shares of Zura Bio from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. Weiss Ratings raised shares of Zura Bio from a “sell (d-)” rating to a “sell (d)” rating in a research note on Wednesday, October 28th. Guggenheim reiterated a “buy” rating on shares of Zura Bio in a research note on Friday, October 30th. Finally, Wedbush boosted their price objective on shares of Zura Bio from $15.00 to $22.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Ethic Inc. acquired a new stake in Zura Bio during the third quarter worth $53,000. Dimensional Fund Advisors LP raised its position in Zura Bio by 83.3% during the first quarter. Dimensional Fund Advisors LP now owns 43,135 shares of the company’s stock valued at $257,000 after purchasing an additional 19,603 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Zura Bio by 2,534.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 124,174 shares of the company’s stock worth $517,000 after purchasing an additional 119,460 shares in the last quarter. Alps Advisors Inc. increased its stake in shares of Zura Bio by 30.7% in the third quarter. Alps Advisors Inc. now owns 126,053 shares of the company’s stock worth $524,000 after purchasing an additional 29,639 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in Zura Bio by 3,007.7% in the 1st quarter. Bank of America Corp DE now owns 136,523 shares of the company’s stock worth $812,000 after buying an additional 132,130 shares during the period. Institutional investors and hedge funds own 61.14% of the company’s stock.

Zura Bio Stock Up 9.9%

Shares of ZURA stock opened at $4.09 on Friday. Zura Bio has a 52 week low of $3.25 and a 52 week high of $7.44. The firm has a 50 day moving average of $4.45 and a 200-day moving average of $5.21. The company has a market cap of $391.94 million, a price-to-earnings ratio of -3.65 and a beta of 0.03.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings results on Tuesday, October 27th. The company reported ($0.20) earnings per share for the quarter, meeting the consensus estimate of ($0.20). Analysts anticipate that Zura Bio will post -0.82 earnings per share for the current year.

About Zura Bio

Zura Bio, Ltd. is a clinical-stage biotechnology company focused on developing medicines for immune-mediated diseases. The company’s research and development programs are designed to address conditions in which abnormal immune-system activity contributes to inflammation and tissue damage.

Zura Bio’s lead investigational product, ZT-101, formerly known as ZB-106 or tibulizumab, is a dual-antagonist antibody designed to inhibit signaling associated with interleukin-17A and B-cell activating factor.